Lexicon Pharmaceuticals will present additional efficacy data from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) at the American Academy of Neurology (AAN) Annual Meeting in Chicago on April 22, 2026. The presentation will focus on the 10‑mg dose, which the study identified as the optimal dose for Phase 3 development. The 10‑mg dose achieved a nominally significant reduction in average pain at Week 8 versus placebo, with consistent improvements in worst and least daily pain, and was well tolerated over the 8‑week period.
The presentation is a key milestone for pilavapadin, a non‑opioid treatment that could become the first drug of its kind for DPNP in more than two decades. The data support the drug’s potential to address a market where roughly 70 % of patients fail existing therapies, underscoring the unmet need that pilavapadin seeks to fill.
In Q4 2025, Lexicon reported an earnings per share of –$0.04 versus analyst expectations of –$0.07, and revenue of $5.49 million versus $3.14 million expected. The company’s net loss narrowed to $50.3 million from $200.4 million in 2024, driven by reduced operating expenses and strategic cost management. These results demonstrate an improving financial position that will support the upcoming Phase 3 program.
Management highlighted the significance of the data and the company’s broader strategy. Dr. Suma Gopinathan said, "We appreciate the opportunity to present additional efficacy data from the PROGRESS study to the neurology community." She added, "These results demonstrate that pilavapadin 10 mg achieved a meaningful reduction in average pain at Week 8, with consistent improvements across other pain measures, supporting its advancement into Phase 3 development in diabetic peripheral neuropathic pain." CEO Mike Exton noted, "Our End‑of‑Phase 2 meeting with FDA was productive and provided Lexicon with the insights needed to design a robust Phase 3 program, with the goal of making the first non‑opioid DPNP medicine available to patients in over two decades." He also emphasized the company’s momentum, saying, "The fourth quarter of 2025 marked the completion of an incredible year for Lexicon. We made substantial progress on all aspects of the business by advancing our pipeline programs, establishing strong development and commercialization agreements with leading global collaborators, working closely with regulators, and remaining operationally efficient. As a result, we have begun 2026 with tremendous momentum and are well‑positioned to successfully execute on multiple important catalysts ahead."
The market reacted positively to the announcement, reflecting investor confidence in the drug’s potential and the company’s improving financial position. The presentation is expected to reinforce Lexicon’s pipeline trajectory and support its strategy to bring a first‑in‑class non‑opioid therapy to patients with diabetic peripheral neuropathic pain.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.